Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia

Health Technology Assessment

Volumn 21, Issue 43, 2017, Pages 1-218

  Bergman, Hanna ^a   Walker, Dawn Marie ^b   Nikolakopoulou, Adriani ^c   Soares Weiser, Karla ^d   Adams, Clive E ^e  

^a Cochrane ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d University of Nottingham ^*  (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMISULPRIDE; BENZODIAZEPINE; BIPERIDEN; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DIAZEPAM; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TETRABENAZINE; ZIPRASIDONE;

CONSULTATION; DECISION MAKING; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPNOSIS; MENTAL HEALTH; META ANALYSIS; RELAXATION TRAINING; REVIEW; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; DYSKINESIA; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85029230816     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta21430     Document Type: Review

References (274)

1. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 2011;100:601-16. http://dx.doi.org/10.1016/B978-0-444-52014-2.00043-4
2. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 2007;191:238-45. https://doi.org/10.1192/bjp.bp.106.035063
3. Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007;68:1901-6. https://doi.org/10.4088/JCP.v68n1210
4. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: 4th Generation of Progress. New York, NY: Raven Press; 1995. URL: www.acnp.org/g4/GN401000143/Default.htm (accessed 20 July 2017).
5. Bakker PR, de Groot IW, van Os J, van Harten PN. Predicting the incidence of antipsychoticinduced movement disorders in long-stay patients: a prospective study. Epidemiol Psychiatr Sci 2013;22:375-9. http://dx.doi.org/10.1017/S204579601300019X
6. Bakker PR, de Groot IW, van Os J, van Harten PN. Antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. Schizophr Res 2014;153(Suppl 1):88-9. https://doi.org/10.1016/S0920-9964(14)70282-8
7. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal sideeffects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-88. http://dx.doi.org/10.1192/bjp.bp.108.050088
8. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463-74. https://doi.org/10.4088/JCP.07m03890yel
9. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 2011;36:1738-46. http://dx.doi.org/10.1038/npp.2011.55
10. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11:166-76. https://doi.org/10.1007/s13311-013-0222-5
11. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012;18(Suppl 5):1-20. https://doi.org/10.18553/jmcp.2012.18.s5-b.1
12. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000;20:188-94. https://doi.org/10.1097/00004714-200004000-00011
13. Martins ES, Rosso A, Coutinho E, Adams C, Huf G. Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro. Rev Psiquiatr Clin 2011;38:44.
14. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178. 2014. URL: www.nice.org.uk/guidance/cg178 (accessed 20 January 2017).
15. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 10th edn. London: Informa Healthcare; 2009. https://doi.org/10.3109/9780203092835
16. Lieberman JA, Fleishhacker W. Introduction. Br J Psychiatry 1996;168(Suppl 29):7-8. https://doi.org/10.1142/9789812819796_0001
17. Chouinard G, Chouinard V-A. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008;77:69-77. https://doi.org/10.1159/000112883
18. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000459. http://dx.doi.org/10.1002/14651858.CD000459.pub2
19. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry 2007;164:1648-54. https://doi.org/10.1176/appi.ajp.2007.07071150
20. Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-based approaches? Mov Disord 2014;29:1404-13. http://dx.doi.org/10.1002/mds.26014
21. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623-6. https://doi.org/10.1136/bmj.319.7210.623
22. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev 2009;3:CD006456. https://doi.org/10.1002/14651858.cd006456.pub2
23. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458. https://doi.org/10.1002/14651858.cd000458.pub2
24. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopainduced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Bio Psychiatry 1993;34:713-38. https://doi.org/10.1016/0006-3223(93)90044-E
25. Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects. In Barnes TRE, ed. Antipsychotic Drugs and their Side-Effects. London: Academic Press/Harcourt Brace & Company; 1993. pp. 231-48. https://doi.org/10.1016/B978-0-12-079035-7.50021-X
26. Gunne LM, Häggström JE, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347-9. https://doi.org/10.1038/309347a0
27. Gardos G, Cole JO. The treatment of tardive dyskinesia. In Bloom FE, DJ K, eds. Psychopharmacology The Fourth Generation of Progress. New York, NY: Raven Press; 1994. URL: www.acnp.org/g4/GN401000145/Default.htm (accessed 20 July 2017).
28. American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
29. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988;8(Suppl 4):38-48. https://doi.org/10.1097/00004714-198808001-00008
30. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002;1:CD001950.
31. Rotrosen J, Adler L, Lohr J, Edson R, Lavori P. Antioxidant treatment of tardive dyskinesia. Prostaglandins Leukot Essent Fatty Acids 1996;55:77-81. https://doi.org/10.1016/S0952-3278(96) 90149-0
32. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989;570:176-85. https://doi.org/10.1111/j.1749-6632.1989.tb14918.x
33. Feltner DE, Hertzman M. Progress in the treatment of tardive dyskinesia: theory and practice. Hosp Community Psychiatry 1993;44:25-34.
34. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-15. https://doi.org/10.1093/schbul/19.2.303
35. Queiroz CM, Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:1405-18. https://doi.org/10.1016/S0278-5846 (99)00074-3
36. Haleem DJ, Samad N, Haleem MA. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav 2007;87:115-21. https://doi.org/10.1016/j.pbb.2007.04.007
37. Wahbeh H, Elsas SM, Oken BS. Mind-body interventions: applications in neurology. Neurology 2008;70:2321-8. http://dx.doi.org/10.1212/01.wnl.0000314667.16386.5e
38. Ajimsha MS, Majeed NA, Chinnavan E, Thulasyammal RP. Effectiveness of autogenic training in improving motor performances in Parkinson’s disease. Complement Ther Med 2014;22:419-25. http://dx.doi.org/10.1016/j.ctim.2014.03.013
39. Franklin SA, Walther MR, Woods DW. Behavioral interventions for tic disorders. Psychiatr Clin North Am 2010;33:641-55. http://dx.doi.org/10.1016/j.psc.2010.04.013
40. Elkins G, Sliwinski J, Bowers J, Encarnacion E. Feasibility of clinical hypnosis for the treatment of Parkinson’s disease: a case study. Int J Clin Exp Hypn 2013;61:172-82. http://dx.doi.org/10.1080/00207144.2013.753829
41. McGrath J, Davies G, Soares K. Writing to authors of systematic reviews elicited further data in 17% of cases. BMJ 1998;316:631. https://doi.org/10.1136/bmj.316.7131.631a
42. Soares K, McGrath J, Adams C. Evidence and tardive dyskinesia. Lancet 1996;347:1696-7. https://doi.org/10.1016/S0140-6736(96)91525-1
43. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203. http://dx.doi.org/10.1002/14651858.CD000203.pub3
44. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;3:CD000205. http://dx.doi.org/10.1002/14651858. CD000205.pub2
45. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206. http://dx.doi.org/10.1002/14651858.CD000206.pub3
46. Soares-Weiser K, Irving Claire B, Rathbone J. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003;2:CD000208. https://doi.org/10.1002/14651858.cd000208
47. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2:CD000209. http://dx.doi.org/10.1002/14651858. CD000209.pub2
48. Soares-Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 1997;2:CD000204. https://doi.org/10.1002/14651858.cd000204
49. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev 2002;3:CD000207. https://doi.org/10.1002/14651858.cd000207
50. Soares KV, McGrath JJ. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999;39:1-16. https://doi.org/10.1016/S0920-9964(99)00021-3
51. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013;7:1329-40. http://dx.doi.org/10.2147/DDDT.S32328
52. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7. http://dx.doi.org/10.7326/0003-4819-159-2-201307160-00008
53. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London: The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 11 April 2017).
54. Adamd CE, Walker D-M, Gray B, Shokraneh F. Appendix: Traceable Extracted Data from Included Studies of Tardive Dyskinesia Reviews. 2016. URL: www.researchgate.net/publication/308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_Reviews?channel=doi&linkId=57ebe1c508ae92a5dbd051c1&showFulltext=true (accessed 13 June 2017).
55. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812. https://doi.org/10.2466/pr0.1962.10.3.799
56. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
57. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19. https://doi.org/10.1111/j.1600-0447.1970.tb02066.x
58. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100. https://doi.org/10.1111/j.1600-0447.1987.tb10566.x
59. Higgins JPT, Ramsay C, Reeves BC, Deeks JJ, Shea B, Valentine JC, et al. Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Methods 2013;4:12-25. https://doi.org/10.1002/jrsm.1056
60. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000;176:249-52. https://doi.org/10.1192/bjp.176.3.24961.
61. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31:140-9. https://doi.org/10.1093/ije/31.1.140
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. http://dx.doi.org/10.1136/bmj.327.7414.557
63. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996;15:2733-49. https://doi.org/10.1002/(SICI)1097-0258(19961230)15:24%3C2733::AIDSIM562% 3E3.0.CO;2-0
64. Raudenbush SW. Analyzing Effect Sizes: Random Effects Models. In Cooper H, Hedges LV, Valentine C, eds. The Handbook of Research Synthesis and Meta-Analysis. New York, NY: Russel Sage Foundation; 2009. pp. 295-316.
65. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med 2007;26:37-52. http://dx.doi.org/10.1002/sim.2514
66. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013;66:158-72. http://dx.doi.org/10.1016/j.jclinepi.2012.01.012
67. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-16. http://dx.doi.org/10.1016/j.jclinepi.2011.06.004
68. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol 2013;66:736-42. http://dx.doi.org/10.1016/j.jclinepi.2013.02.004
69. Sutton AJ, Cooper NJ, Jones DR, Lambert PC, Thompson JR, Abrams KR. Evidence-based sample size calculations based upon updated meta-analysis. Stat Med 2007;26:2479-500. http://dx.doi. org/10.1002/sim.2704
70. Langan D, Higgins JP, Gregory W, Sutton AJ. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 2012;65:511-19. http://dx.doi.org/10.1016/j.jclinepi.2011.10.009
71. Cai N. [A controlled study on the treatment of tardive dyskinesia using 1-stepholidine.] Zhonghua Shen Jing Jing Shen Ke Za Zhi 1988;21:281-3.
72. Chen J, Zhong X, Cao Z. A double-blind auto-control study on the effect of bromocriptine on tardive dyskinesia. Chin J Pharmacoepidemiol 1995;4:203-5.
73. Mei H, Zhu Q. γ-aminobutyric acid in the treatment of 20 cases of tardive dyskinesia. Herald Med 2008;27:304-5.
74. Shi X, Zhu F, Zhang X, Zhang JX, Zhang XM, Wei LH, et al. Melatonin in treatment of schizophrenia with tardive dyskinesia: a comparison study of cognitive function. Linchuang Jingshen Yixue Zazhi 2009;19:391-3.
75. Xiang H, Zhen C. Clonazepam therapy of tardive dyskinesia: a double-blind trial. West China Med J 1997;12:17-18.
76. Yang X, Meng F, Cui Y. Promethazine treatment of tardive dyskinesia: a double blind placebo controlled study. Chin Ment Health J 1999;13:365-7.
77. Yin XR, Xie BQ, Jiang L. A double-blind comparative study of sodium valproate in treating of TD. J Clin Psychol Med 2004;14:92-3.
78. Zeng ZX. Treatment of tardive dyskinesia with buspirone. Med J Chinese Civil Admin 1995;7:202-3.
79. Zeng ZX. Pemoline in the treatment of tardive dyskinesia. Chin J New Drugs Clin Remedies 1996;15:240-1.
80. Zeng ZX, Li ZC, Yu XW, Zhang YD, Cao ZC. A double-blind trial of flunarizine therapy for tardive dyskinesia. Chin J Pharmaco Epidemiol 1994;3:183-4.
81. Hebenstreit GF, Hoffmann H, Hoffmann W, Pittner H. [Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics.] Wien Klin Wochenschr 1986;98:388-92.
82. Kocher R, Hobi V, Linder M, Studer K. [Treatment with dimethylaminoethanol (deanol) in neuroleptic induced tardive dyskinesia.] Schweiz Arch Neurol Neurochir Psychiatr 1980;126:103-9.
83. Lucius G. Uber die Therapeutische Wirksamkeit von Dimethylaminoaethanol bei Neuroleptikainduzierten Späthyperkinesen. Dissertation. Freiburg im Breisgau: Albert Ludwigs University of Freiburg; 1978.
84. Koshino Y, Hiramatsu H, Isaki K, Yamaguchi N. A double-blind clinical trial of dihydrogenated ergot alkaloids in antipsychotic-induced tardive dyskinesia. Clin Psychiatry 1983;25:627-35.
85. Koshino Y, Kurata K, Hosokawa K, Yamaguchi N. Double-blind trial of cyproheptadine on neuroleptic induced tardive dyskinesia. Clin Psychiatry 1979;21:421-6.
86. Yagi G, Kamishima K, Miura S. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia-a double-blind placebo-controlled study. Rinsho Hyoka 1990;18:455-79.
87. Jahanian AA, Rezaei O, Fadai F, Yaraghchi A. The effectiveness of rivastigmine in reducing tardive dyskinesia symptoms in patients with schizophrenia. Iran J Psychiatry Clin Psychol 2014;20:29-34.
88. Karniol IG, Giampietro AC, Moura DS, Vilela WA, Oliveira MA, Zuardi AW. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia.] Acta Psiquiatr Psicol Am Lat 1983;29:261-6.
89. Weber SS, Dufresne RL, Becker RE, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm 1983;17:523-7. https://doi.org/10.1177/106002808301700705
90. Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997;41:114-16. https://doi.org/10.1016/S0006-3223(96)00367-8
91. Dorevitch A, Lerner V, Shalfman M, Kalian M. Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia. Int Clin Psychopharmacol 1997;12:171-3. https://doi.org/10.1097/00004850-199705000-00008
92. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-7. http://dx.doi.org/10.1176/ajp.149.6.773
93. Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990;147:505-6. http://dx.doi.org/10.1176/ajp.147.4.505
94. Lam LC, Chiu HF, Hung SF. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis 1994;182:113-14. https://doi.org/10.1097/00005053-199402000-00009
95. Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry 1991;6:201-7.
96. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;130:479-83. http://dx.doi.org/10.1176/ajp.130.4.479
97. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893-6. https://doi.org/10.1001/archpsyc.1983.01790070083010
98. Cookson IB. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol 1987;2:141-9. https://doi.org/10.1097/00004850-198704000-00008
99. Chouinard G, Arnott W. The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biol Psychiatry 1992;31(Suppl 5):158. https://doi.org/10.1016/0006-3223 (92)90579-O
100. Chouinard G, Arnott W. Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clin Neuropharmacol 1992;15(Suppl 1):266. https://doi.org/10.1097/00002826-199202001-00514
101. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15(Suppl 1):36-44. https://doi.org/10.1097/00004714-199502001-00007
102. Chouinard G., Arnott W. An Antidyskinetic Effect of Risperidone. Proceedings of the 9th World Congress of Psychiatry, Rio de Janeiro, 6-12 June, 1993.
103. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40. https://doi.org/10.1097/00004714-199302000-00004
104. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(Suppl B):102-6.
105. Bai YM, Lin CC, Yu SC. Risperidone for severe tardive dyskinesia: one year follow up study. Int J Neuropsychopharmacol 2002;5:S165.
106. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 2005;20:79-85. https://doi.org/10.1097/00004850-200503000-00003
107. Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, 18-23 May 2002.
108. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1342-8. https://doi.org/10.4088/JCP.v64n1110
109. Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, 5-10 May 2001.
110. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696-701. https://doi.org/10.4088/JCP.v65n0516
111. Emsley RA, Turner J, Schronen J, Botha K, Smit R, Oosthuizen PP. Quetiapine: Greater Improvements in Tardive Dyskinesia versus Haloperidol. 157th Annual Meeting of the American Psychiatric Association, New York, NY, 1-6 May 2004.
112. Bai YM, Ping LY, Lin CC, Wang YC, Liou YL, Wu BJ, et al. Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study. Eur Neuropsychopharmacol 2005;15(Suppl 3):473. https://doi.org/10.1016/S0924-977X(05)80979-4
113. Bai YM, Ping LY, Lin CC, Wang YC, Liou YL, Wu BJ, et al. Comparative Effects of Atypical Antipsychotic on Tardive Dyskinesia and Neurocognition: A 24-week Randomized, Single-Blind, Controlled Study. Proceedings of the 8th World Congress of Psychiatry, Cairo, Egypt, 10-15 September 2005.
114. Bai YM. Tardive Dyskinesia and Cognitive Function. 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00926965 (accessed 20 January 2017).
115. Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010;71:1226-33. https://doi.org/10.4088/JCP.09m05155yel
116. NCT00621998. Risperidone and Olanzapine for the Schizophrenic Patients with Neuroleptic-Induced Tardive Dyskinesia. 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00621998 (accessed 20 January 2017).
117. Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 2011;72:295-303. http://dx.doi.org/10.4088/JCP.09m05793yel
118. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33-43. https://doi.org/10.1016/j.schres.2005.07.034
119. Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984;145:304-10. https://doi.org/10.1192/bjp.145.3.304
120. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981;138:189-93. http://dx.doi.org/10.1176/ajp.138.2.189
121. Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 1988;45:655-9. https://doi.org/10.1001/archpsyc.1988.01800310063008
122. Csernansky JG, Tacke U, Rusen D, Hollister LE. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol 1988;8:154-5. https://doi.org/10.1097/00004714-198804000-00028
123. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868-72. https://doi.org/10.1016/S0006-3223(97)00027-9
124. Adler LA, Peselow E, Angrist B, Duncan E, Lee M, Rosenthal M, et al. Vitamin E in Tardive Dyskinesia: Effects of Longer Term Treatment. Proceedings of the 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 14-18 December 1992.
125. Adler LA, Peselow E, Duncan E, Rosenthal M, Angrist B. Vitamin E in tardive dyskinesia: time course of effect after placebo substitution. Psychopharmacol Bull 1993;29:371-4.
126. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150:1405-7. http://dx.doi.org/10.1176/ajp.150.9.1405
127. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993;39:124-6.
128. Dabiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994;151:925-6. http://dx.doi.org/10.1176/ajp.151.6.925
129. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57:167-73.
130. Sajjad SH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol 1998;13:147-55. https://doi.org/10.1097/00004850-199807000-00001
131. Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P. Interrater reliability issues in multicentric trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study 394. Psychopharmacol Bull 1997;33:53-7.
132. Lohr JB, Lavori P. Whither vitamin E and tardive dyskinesia? Biol Psychiatry 1998;43:861-2.
133. Edson R, Lavori P, Tracy K, Adler LA, Rotrosen J. Interrater reliability issues in multicentric trials, part II: statistical procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 1997;33:59-67.
134. Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, Tracy K. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394. Psychopharmacology 1997;132:61-6. https://doi.org/10.1007/s002130050320
135. Adler LA, Rotrosen J, Lavori P, Edson R. Vitamin E treatment of TD: development of a VA cooperative study. Biol Psychiatry 1994;35:730-1. https://doi.org/10.1016/0006-3223(94)91073-1
136. Bridler R. [Vitamin E is ineffective in treatment of late dyskinesias.] Praxis 2001;90:809-10.
137. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999;56:836-41. https://doi.org/10.1001/archpsyc.56.9.836
138. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 2004;24:83-6. http://dx.doi.org/10.1097/01.jcp.0000104912.75206.2b
139. Glover O. Alternative Treatment Modalities for Drug Induced Psychomotor Dysfunctions. PhD thesis. Berkeley, CA: The Wright Institute;1980.
140. Zeng ZX, Fenglian C, Lin L. A clinical research of dexetimide and benzhexol for treatment of drug-induced tremor. Herald Med 1996;15:130-1.
141. Kar-Ahmadi M. Vitamin E in the management of drug induced tardive dyskinesia: a double-blind randomized clinical trial. J Res Med Sci 2002;4:311-20.
142. Garcia G, Crismon ML. Double-blind placebo controlled study using buspirone in the treatment of tardive dyskinesia. ASHP Midyear Clin Meet 1992;27:91.
143. Reynolds C. A Six Month, Rater Blind Comparison of Quetiapine and Risperidone in the Treatment of Tardive Dyskinesia in Patients with Schizophrenia. Leeds: National Research Register; 2002.
144. Kajero J. Investigation of the Potential Beneficial Effects of Cannabidiol in the Treatment of Tardive Dyskinesia. 2015. URL: www.isrctn.com/ISRCTN14688109 (accessed 20 January 2017).
145. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? Mod Probl Pharmacopsychiatry 1983;21:65-79. https://doi.org/10.1159/000408484
146. Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64:170-6. https://doi.org/10.1001/archpsyc.64.2.170
147. Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016;86:651-9. http://dx.doi.org/10.1212/WNL.0000000000002370
148. Hardoy MC, Carta MG, Carpiniello B, Cianchetti C, Congia S, D’Errico I, et al. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord 2003;75:125-30. https://doi.org/10.1016/S0165-0327(02)00043-5
149. Huang CC. Comparison of two groups of tardive dyskinesia patients. Psychiatry Res 1986;19:335-6. https://doi.org/10.1016/0165-1781(86)90128-9
150. Koshino Y, Wada Y, Isaki K, Kurata K. A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication. Clin Neuropharmacol 1991;14:537-46. https://doi.org/10.1097/00002826-199112000-00006
151. Peselow ED, Angrist BM, Rotrosen J. Changes in tardive dyskinesia after fluphenazine decanoate discontinuation. Ann Clin Psychiatry 1989;1:187-91. https://doi.org/10.3109/10401238909149978
152. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia-with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 1985;34:211-19. https://doi.org/10.2302/kjm.34.211
153. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 1992;86:262-6. https://doi.org/10.1111/j.1600-0447.1992.tb03264.x
154. Yassa R, Nair V, Schwartz G. Tardive dyskinesia: a two-year follow-up study. Psychosomatics 1984;25:852-5. https://doi.org/10.1016/S0033-3182(84)72946-X
155. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97. https://doi.org/10.1002/jrsm.1037
156. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012;3:111-25. http://dx.doi.org/10.1002/jrsm.1045
157. Lu G, Welton NJ, Higgins JP, White IR, Ades AE. Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. Res Synth Methods 2011;2:43-60. https://doi.org/10.1002/jrsm.34
158. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77. http://dx.doi.org/10.1002/sim.2528
159. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75. http://dx.doi.org/10.1002/sim.1761
160. Soares MO, Dumville JC, Ades AE, Welton NJ. Treatment comparisons for decision making: facing the problems of sparse and few data. J R Stat Soc Ser A 2014;177:259-79. https://doi.org/10.1111/rssa.12010
161. Rücker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 2009;28:721-38. http://dx.doi.org/10.1002/sim.3511
162. Kuss O. Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless. Stat Med 2015;34:1097-116. https://doi.org/10.1002/sim.6383
163. Warren FC, Abrams KR, Golder S, Sutton AJ. Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event. BMC Med Res Methodol 2012;12:64. http://dx.doi.org/10.1186/1471-2288-12-64
164. Fleiss JL. The Crossover Study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley & Sons; 1984.
165. Armitage P. Should we cross off the crossover? Br J Clin Pharmacol 1991;32:1-2. https://doi.org/10.1111/j.1365-2125.1991.tb05604.x
166. Pocock SJ. Crossover Trials. Clinical Trials A Practical Approach. Chichester: John Wiley & Sons; 1983.
167. Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial justified? BMJ 2012;345:e5913. http://dx.doi.org/10.1136/bmj.e5913
168. Clarke M. Doing new research? Don’t forget the old. PLOS Med 2004;1:e35. http://dx.doi.org/10.1371/journal.pmed.0010035
169. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 1972;27:100-3. https://doi.org/10.1001/archpsyc.1972.01750250086012
170. Borenstein M, Hedges LV, Higgins JPT. Introduction to Meta-Analysis. Chichester: John Wiley & Sons; 2011.
171. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71. http://dx.doi.org/10.1016/j.jclinepi.2010.03.016
172. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 2015;15:58. http://dx.doi.org/10.1186/s12874-015-0060-8
173. Higgins JP, Green S, Scholten RJ. Maintaining Reviews: Updates, Amendments and Feedback. In Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, Ltd; 2008. pp. 31-49. https://doi.org/10.1002/9780470712184.ch3
174. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013;11:159. http://dx.doi.org/10.1186/1741-7015-11-159
175. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. https://doi.org/10.1016/0197-2456(86)90046-2
176. White IR. Network meta-analysis. Stata J 2015;15:951-85.
177. Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. http://dx.doi.org/10.1002/jrsm.1058
178. Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med 2014;33:4353-69. http://dx.doi.org/10.1002/sim.6236
179. R Development Core Team. R: A Language and Environment for Statistical Computing. 2008. URL: www.r-project.org/(accessed 11 April 2017).
180. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network metaanalysis in STATA. PLOS ONE 2013;8:e76654. http://dx.doi.org/10.1371/journal.pone.0076654
181. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012;41:818-27. https://doi.org/10.1093/ije/dys041
182. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 2015;68:52-60. http://dx.doi.org/10.1016/j.jclinepi.2014.08.012
183. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. https://doi.org/10.1016/S0895-4356(97)00049-8
184. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. http://dx.doi.org/10.1002/jrsm.1044
185. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med 2014;33:3639-54. http://dx.doi.org/10.1002/sim.6188
186. Hempel S, Miles JN, Booth MJ, Wang Z, Morton SC, Shekelle PG. Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis. Syst Rev 2013;2:107. http://dx.doi.org/10.1186/2046-4053-2-107
187. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 2012;3:161-76. http://dx.doi.org/10.1002/jrsm.57
188. Lublin H, Gerlach J, Hagert U, Meidahl B, Mølbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol 1991;1:541-8. https://doi.org/10.1016/0924-977X(91) 90008-I
189. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 1990;3:315-20. https://doi.org/10.1016/0920-9964(90)90016-Z
190. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry 1985;46:4-7.
191. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 2000.
192. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7. https://doi.org/10.1001/archpsyc.1982.04290040080014
193. American Psychiatric Association. DSM-IIl-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd edn, revised. Washington, DC: American Psychiatric Association; 1987.
194. National Center for Health Statistics. Classification of Diseases and Injuries. 2002. URL: ftp://ftp. cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD-9/ucod.txt (accessed on 6 June 2017).
195. Chinese Medical Association and Nanjing Medical University. Chinese Classification of Mental Disorders, Second Edition, Revised (CCMD-2-R). Nanjing: Dong Nan University Press; 1995.
196. World Health Organization. The Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. URL: www.who.int/classifications/icd/en/bluebook.pdf (accessed 20 July 2017).
197. Bucci L. The dyskenesias: a new therapeutic approach. Dis Nerv Syst 1971;32:324-7.
198. Loonen AJM, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial. J Clin Psychopharmacol 1992;12:39-42. https://doi.org/10.1097/00004714-199202000-00007
199. Schwartz B, McCarthy MF, Kendrick K, Rosse R, Deutsch S. Effect of nifedipine on motor skill learning in schizophrenia. Schizophr Res 1997;24:125. https://doi.org/10.1016/S0920-9964(97) 82352-3
200. Schwartz BL, Fay-McCarthy M, Kendrick K, Rosse RB, Deutsch SI. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. Clin Neuropharmacol 1997;20:364-70. https://doi.org/10.1097/00002826-199708000-00009
201. Beckham BJ. Lecithin Therapy for Tardive Dyskinesia. Dissertation. Denton, TX: North Texas State University; 1981.
202. Caroff SN, Walker P, Campbell C, Lorry A, Petro C, Lynch K, Gallop R. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007;68:410-15.
203. Caroff SN. Treatment of Tardive Dyskinesia with Galantamine. 2005. URL: https://clinicaltrials.gov/ct2/show/NCT00164242 (accessed 20 January 2017).
204. de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology 1979;65:219-23. https://doi.org/10.1007/BF00492207
205. Gelenberg AJ, Dorer DJ, Wojcik JD, Falk WE, Brotman AW, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-53.
206. George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry 1981;15:68-71. https://doi.org/10.3109/00048678109159413
207. Jackson IV. Cholinergic enhancement in tardive dyskinesia. Curr Ther Res Clin Exp 1978;24:725-33.
208. Jackson IV, Davis LG, Cohen RK, Nuttall EA. Lecithin administration in tardive dyskinesia: clinical and biomedical correlates. Biol Psychiatry 1981;16:85-90.
209. Jackson IV, Nuttall EA, Ibe IO, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry 1979;136:1458-60. http://dx.doi.org/10.1176/ajp.136.11.1458
210. Bockenheimer S, Lucius G. [Deanol in tardive dyskinesia: a double-blind study.] Arch Psychiatr Nervenkr 1976;222:69-75. https://doi.org/10.1007/BF00369796
211. Ogunmefun A, Hasnain M, Alam A, Osuala T, Regenold WT. Effect of donepezil on tardive dyskinesia. J Clin Psychopharmacol 2009;29:102-4. http://dx.doi.org/10.1097/JCP.0b013e3181934475
212. Price LA. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation. Dissertation. Denton, TX: North Texas State University; 1982.
213. Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol 1977;34:756-8. https://doi.org/10.1001/archneur.1977.00500240044007
214. Ojima Y, Tsubaki M, Yagi G, Kamishima K, Miura S. Experimental design and analysis for determination of improvement rating by video imaging-a double-blind placebo-controlled study for Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia. Rinsho Hyoka 1991;19:267-76.
215. Yagi G, Kamizima K, Miura S. Meclofenoxate (Lucidril) in Tardive Dyskinesia-A Double-Blind Placebo-Controlled Study. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress, Kyoto, Japan, September 10-14 1990.
216. Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia. Curr Ther Res Clin Exp 1987;42:111-14.
217. Burner M, Giroux C, L’Heritier C, Garreau M, Morselli PL. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunct 1989;2:289-96.
218. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry 1987;150:542-6. https://doi.org/10.1192/bjp.150.4.542
219. Gerlach J. The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 1977;134:781-4. http://dx.doi.org/10.1176/ajp.134.7.781
220. Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology 1978;56:145-51. https://doi.org/10.1007/BF00431840
221. Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985;87:480-3. https://doi.org/10.1007/BF00432517
222. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-19. https://doi.org/10.1192/bjp.129.2.114
223. Nair NP, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry 1978;135:1562-3. http://dx.doi.org/10.1176/ajp.135.12.1562
224. Nair NP, Lal S, Schwartz G, Thavundayil JX. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Adv Biochem Psychopharmacol 1980;24:437-41.
225. Stewart RM, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol 1982;5:365-73. https://doi.org/10.1097/00002826-198212000-00004
226. Stewart RM, Rollins J, Beckam B, Roffman M. Baclofen for tardive dyskinesia: a double-blind placebo-controlled trial. Neurology 1982;32:A114.
227. Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gammaaminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry 1987;44:522-9. https://doi.org/10.1001/archpsyc.1987.01800180032006
228. Castro F, Carrizo E, Prieto de Rincón D, Rincón CA, Asián T, Medina-Leendertz S, Bonilla E. Effectiveness of melatonin in tardive dyskinesia. Invest Clin 2011;52:252-60.
229. Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 2006;84:112-20. https://doi.org/10.1016/j.schres.2006.03.023
230. Elmsley R, Oosthuizen PP. Double-Blind, Randomized, Parallel-Group Comparison of Ethyleicosapentaenoic Acid (ethyl-EP A) versus Placebo as add-on Medication in 84 Patients with Established Tardive Dyskinesia. Muscatine, IA: Stanley Foundation Research Programs; 2002.
231. Emsley R. Ethyl Eicosapentanoic Acid for Tardive Dyskinesia. Muscatine, IA: Stanley Foundation Research Programs; 2009.
232. NCT00114595. A Double-Blind, Randomised, Parallel-Group Comparison of Ethyleicosapentaenoic Acid (ethyl-epa) versus Placebo as add-on Medication in Patients with Established Tardive Dyskinesia. 2005. URL: https://clinicaltrials.gov/ct2/show/NCT00114595 (accessed 20 January 2017).
233. Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, et al. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res 2008;161:284-91. http://dx.doi.org/10.1016/j.psychres.2007.06.029
234. Gardos G, Granacher RP, Cole JO, Sniffin C. The effects of papaverine in tardive dyskinesia. Prog Neuropsychopharmacol 1979;3:543-50. https://doi.org/10.1016/0364-7722(79)90008-0
235. Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 1985;10:345-50. https://doi.org/10.1016/0306-4530(85)90011-3
236. Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993;33:700-6. https://doi.org/10.1016/0006-3223(93)90119-X
237. Hajioff J, Wallace M. Effect of co-dergocrine mesylate on tardive dyskinesia. A preliminary report. Psychopharmacology 1983;79:1-3. https://doi.org/10.1007/BF00433006
238. Kojima T, Yamauchi T, Miyasaka M, Isaki K, Nakane Y, Takahashi R, et al. Treatment of tardive dyskinesia with ceruletide: a double-blind placebo-controlled study. Saishin-Igaku 1989;44:2177-88.
239. Kojima T, Yamauchi T, Miyasaka M, Koshino Y, Nakane Y, Takahashi R, et al. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res 1992;43:129-36. https://doi.org/10.1016/0165-1781(92)90127-O
240. Lerner V. Piracetam for Tardive Dyskinesia. Muscatine, IA: Stanley Foundation Research Programs; 2009.
241. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68:1031-7. https://doi.org/10.4088/JCP.v68n0709
242. Anon. Piracetam reduces TD symptoms tardive dyskinesia. Brown Uni Psychopharmacol Update 2007;18:3-4.
243. NCT00190008. Therapeutic use of Piracetam for Treatment of Patients Suffering from Tardive Dyskinesia-A Double Blind, Placebo-Controlled Crossover Study. 2005. URL: https://clinicaltrials. gov/ct2/show/NCT00190008 (accessed 20 January 2017).
244. MacKay AV, Sheppard GP, Saha BK, Motley B, Johnson AL, Marsden CD. Failure of lithium treatment in established tardive dyskinesia. Psychol Med 1980;10:583-7. https://doi.org/10.1017/S0033291700047498
245. Matsunaga T, Ohyama S, Takehara S, Kabashima K, Moriyama S, Tsuzuki J, et al. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:533-9. https://doi.org/10.1016/0278-5846(88)90112-1
246. Meco G, Bedini L, Bonifati V, Sonsini U. Ritanserin in tardive dyskinesia: a double-blind crossover study versus placebo. Curr Ther Res Clin Exp 1989;46:884-94.
247. Mosnik DM, Spring B, Rogers K, Baruah S, Waziri R. Phenylalanine loading effects on tardive dyskinesia severity in schizophrenics. Schizophr Res 1995;15:208. https://doi.org/10.1016/0920-9964(95)95640-U
248. Mosnik DM. Phenylalanine Loading Effects on Tardive Dyskinesia Severity in Schizophrenics. Master of Science dissertation. North Chicago, IL: Finch University of Health Sciences; 1994.
249. Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46. https://doi.org/10.1016/S0893-133X(96)00054-1
250. Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur Neurol 1991;31:199-203. https://doi.org/10.1159/000116678
251. O’Brien CF, Jimenez R, Hauser RA, Factor SA, Mandri DF, Castro-Gyol JC. Kinect 2: NBI-98854 Treatment of Moderate to Severe Tardive Dyskinesia. 18th International Congress of Parkinson’s Disease and Movement Disorders, Stockholm, Sweden, 2014.
252. NCT01733121. Nbi-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia. 2012. URL: http://ClinicalTrials.gov/show/NCT01733121 (accessed 20 January 2017).
253. Rastogi SC, Blowers AJ, Gibson AC. Co-dergocrine (hydergine) in the treatment of tardive dyskinesia. Psychol Med 1982;12:427-9. https://doi.org/10.1017/S0033291700046778
254. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-24. http://dx.doi.org/10.1176/appi.ajp.160.6.1117
255. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 2000;61:556-8. https://doi.org/10.4088/JCP.v61n0803
256. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-52. https://doi.org/10.1001/archpsyc.58.11.1049
257. Shamir EZ, Barak F, Shalman I, et al. Melatonin Treatment for Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Cross-Over Study. Annual Meeting of the American Psychiatric Association, Los Angeles, CA, USA, 5-10 May 2001.
258. NCT00175955. An 8-week Exploratory, Double-Blind, Placebo Controlled, Randomized Trial-Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/day (250-500 mg Oral Tablets in Bid Administration) on Neuroleptic-Induced Tardive Dyskinesia in Subjects with Stable Axis I Psychiatric Disorder, Aged from at least 18 Years to 80 Years. 2005. URL: https://clinicaltrials.gov/ct2/show/NCT00175955 (accessed 20 January 2017).
259. Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 1986;143:912-14. http://dx.doi.org/10.1176/ajp.143.7.912
260. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69:546-54. https://doi.org/10.4088/JCP.v69n0405
261. NCT00291213. Levetiracetam Treatment of Tardive Dyskinesia. 2006. URL: https://clinicaltrials. gov/ct2/show/NCT00291213 (accessed 20 January 2017).
262. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:615-21. http://dx.doi.org/10.4088/JCP.09m05125yel
263. Zhang F, Bigos K, Weinberger D. Genome-Wide Analysis of Antipsychotic Drug Response in Schizophrenia. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, HI, USA, 4-8 December 2011.
264. Tan Y. Extract of Ginkgo biloba and Tardive Dyskinesia. 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00672373 (accessed 20 January 2017).
265. Buruma OJ, Roos RA, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand 1982;65:38-44. https://doi.org/10.1111/j.1600-0404.1982.tb03059.x
266. Roos RAC, Buruma OJS, Bruyn GW, Kemp B, van der Velde EA, Zelvelder WG. [Tiapride in Huntington's chorea and tardive dyskinesia. A double-blind, placebo controlled crossover clinical trial.] J Drug Res 1982;7:1234-9.
267. Huang CC, Wang RI, Hasegawa A, Alverno L. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull 1980;16:41-3.
268. Huang CC, Wang RI, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology 1981;73:359-62. https://doi.org/10.1007/BF00426466
269. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33:271-5. https://doi.org/10.1097/WNF.0b013e3181ffde32
270. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Biol Psychiatry 2009:171.
271. Pappa S, Tzouli S, Mavreas V, Konitsiotis S. Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2012;136:S358. https://doi.org/10.1016/S0920-9964(12)71045-9
272. Rust M. Tiapride treatment of tardive dyskinesia due to long-term neuroleptic treatment. Sem Hop 1984;60:2195-6.
273. Simpson GM, Yadalam KG, Stephanos MJ. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia. J Clin Psychopharmacol 1988;8(Suppl 4):49-51. https://doi.org/10.1097/00004714-198808001-00009
274. Soni SD, Freeman HL, Bamrah JS, Sampath G. Oxypertine in tardive dyskinesia: a long-term controlled study. Acta Psychiatr Scand 1986;74:446-50. https://doi.org/10.1111/j.1600-0447. 1986.tb06267.x